Reni Benjamin
Stock Analyst at Citizens
(1.37)
# 3,595
Out of 5,090 analysts
164
Total ratings
37.96%
Success rate
-14.2%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $5.60 | +78.57% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $7.19 | +66.90% | 15 | Oct 31, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.44 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $86.96 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.56 | +257.21% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.84 | +19.52% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $103.19 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.54 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.97 | +311.02% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.54 | +160.59% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $4.24 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.12 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.77 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $19.87 | -49.67% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $5.09 | -1.67% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $11.86 | +136.09% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $10.76 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $18.33 | +118.28% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.23 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.46 | +174.82% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.65 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.52 | -15.97% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $46.99 | +27.70% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.02 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $220.00 | +43.18% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $92.03 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $263.07 | +0.73% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.26 | +299.06% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $13.03 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.39 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $31.06 | -61.37% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $22.99 | - | 1 | Nov 15, 2017 |
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $5.60
Upside: +78.57%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $7.19
Upside: +66.90%
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.44
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $86.96
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.56
Upside: +257.21%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.84
Upside: +19.52%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $103.19
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.54
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.97
Upside: +311.02%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.54
Upside: +160.59%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.24
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.12
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.77
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $19.87
Upside: -49.67%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $5.09
Upside: -1.67%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $11.86
Upside: +136.09%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $10.76
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $18.33
Upside: +118.28%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.23
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.46
Upside: +174.82%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $8.65
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.52
Upside: -15.97%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $46.99
Upside: +27.70%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.02
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $220.00
Upside: +43.18%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $92.03
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $263.07
Upside: +0.73%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.26
Upside: +299.06%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $13.03
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.39
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $31.06
Upside: -61.37%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $22.99
Upside: -